Drugs / XFB19
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05361733 | Feb → Sep 2026 overdue | — | Xfibra, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XFB19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05361733 ↗ |
| Action | Inhibit | “effectively, safely, and selectively inhibits phospho-C/EBPβThr266” NCT05361733 ↗ |
| Route | Subcutaneous | “XFB19 SC injection” NCT05361733 ↗ |